SI-BONE, Inc. (NASDAQ:SIBN) Shares Sold by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. lowered its holdings in SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 36.7% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 532,712 shares of the company's stock after selling 308,333 shares during the quarter. Harbor Capital Advisors Inc. owned about 1.25% of SI-BONE worth $7,474,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in SIBN. Virtus Fund Advisers LLC purchased a new position in SI-BONE in the fourth quarter valued at approximately $40,000. Mainstream Capital Management LLC acquired a new position in shares of SI-BONE in the 4th quarter valued at $53,000. GAMMA Investing LLC grew its position in shares of SI-BONE by 20,352.6% in the 1st quarter. GAMMA Investing LLC now owns 3,886 shares of the company's stock valued at $55,000 after buying an additional 3,867 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in SI-BONE during the 4th quarter worth $97,000. Finally, Proficio Capital Partners LLC acquired a new stake in SI-BONE during the 4th quarter worth $155,000. Institutional investors and hedge funds own 98.11% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Cantor Fitzgerald restated an "overweight" rating and issued a $25.00 price objective on shares of SI-BONE in a research note on Tuesday, May 6th. Truist Financial boosted their target price on SI-BONE from $20.00 to $22.00 and gave the company a "buy" rating in a report on Tuesday, May 6th. Finally, Needham & Company LLC restated a "buy" rating and set a $24.00 target price on shares of SI-BONE in a research report on Tuesday, May 6th.

SI-BONE Stock Performance

Shares of NASDAQ SIBN traded down $0.84 during midday trading on Friday, reaching $17.42. 1,592,400 shares of the company were exchanged, compared to its average volume of 388,182. The stock has a market cap of $742.35 million, a P/E ratio of -18.93 and a beta of 0.94. SI-BONE, Inc. has a 1 year low of $11.70 and a 1 year high of $20.05. The stock has a fifty day simple moving average of $16.59 and a 200 day simple moving average of $15.72. The company has a current ratio of 8.25, a quick ratio of 7.22 and a debt-to-equity ratio of 0.22.

SI-BONE (NASDAQ:SIBN - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.09. The company had revenue of $47.29 million for the quarter, compared to analyst estimates of $45.13 million. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. On average, research analysts forecast that SI-BONE, Inc. will post -0.78 earnings per share for the current fiscal year.

Insider Transactions at SI-BONE

In related news, Director Jeffrey W. Dunn sold 3,377 shares of SI-BONE stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $19.05, for a total transaction of $64,331.85. Following the completion of the sale, the director now owns 17,354 shares in the company, valued at approximately $330,593.70. This trade represents a 16.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Laura Francis sold 38,504 shares of SI-BONE stock in a transaction dated Wednesday, May 7th. The stock was sold at an average price of $17.18, for a total transaction of $661,498.72. Following the sale, the chief executive officer now owns 302,958 shares of the company's stock, valued at approximately $5,204,818.44. This trade represents a 11.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 95,942 shares of company stock valued at $1,734,203 over the last three months. 4.00% of the stock is currently owned by insiders.

SI-BONE Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.